A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
This study is ongoing, but not recruiting participants.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
First received: March 27, 2012
Last updated: February 7, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||July 2018|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||February 2, 2017|